Cannabis Rescheduling Could Boost Profits By 25% If Federal Tax Rules Change, Says Expert

With federal cannabis rescheduling possibly on the horizon, industry leaders are analyzing the potential impacts this regulatory shift could have on the financial landscape of cannabis businesses.

Experts have weighed in on the potential implications of rescheduling, particularly concerning access to traditional banking services and capital markets. One such expert, Laurie Parfitt, founder and CEO of LKP Impact Consulting and upcoming speaker at the Benzinga Cannabis Capital Conference, offers a detailed perspective on how these changes might affect the industry.

Financial Ramifications Of Rescheduling

The potential removal of the federal tax provision 280E is a critical point of discussion in the rescheduling debate. Parfitt highlights that eliminating 280E could lead to a 20-25% increase in the bottom lines of cannabis businesses. However, she remains cautious, noting that the federal government may not entirely forgo this revenue source without introducing an alternative, such as an excise tax. “While this might be less burdensome, it would still present challenges for the industry,” Parfitt explains.

Parfitt also highlights that rescheduling alone may not fully address the industry’s need for safer banking and more traditional capital access. "Rescheduling does not equate to federal legalization," she says, pointing out that the move might enhance investor confidence but won’t resolve all the financial hurdles cannabis businesses face.

Opportunities and Challenges

While rescheduling could open the door to more comprehensive research and education about cannabis, Parfitt also warns of potential challenges. “Rescheduling would likely lead to more extensive research and better education for medical professionals,” she says, particularly concerning cannabis's medical benefits and the endocannabinoid system.

However, Parfitt advises caution, especially for companies that have made poor financial decisions. She notes that some might view rescheduling as a “panacea,” leading to a false sense of security. Additionally, she raises concerns that rescheduling could delay federal legalization, prolonging the regulatory complexities businesses currently navigate.

Industry Perspectives

As the cannabis industry anticipates possible regulatory changes, Parfitt’s insights highlight the mixed implications of rescheduling. Her thoughts and other industry leaders will be part of the ongoing discussions at the upcoming Benzinga Cannabis Capital Conference in Chicago, scheduled for Oct. 8-9, 2024. The event will bring together critical voices from the cannabis industry to explore the potential impacts of these evolving regulations.

Read Next:

• Cannabis Stocks Plummet By Up To 16% On DEA Rescheduling Delay: Could This Be The Buying Opportunity Of 2024?

Photo: Courtesy of Plateresca via Shutterstock